Pre-surgery immunotherapy kept a group of bowel cancer patients cancer-free for nearly three years, while personalized blood tests helped predict treatment response. Patients with a specific form of bowel cancer who received a short course of immunotherapy before surgery, rather than chemotherapy afterward, have remained cancer-free for nearly three years, according to updated findings from [...]

An unusual immune signature in lung cancer has led researchers toward a potential therapy involving tumor microbes and MAIT cells. Bacteria living inside lung tumors may be doing more than simply occupying the tumor environment. In preclinical research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, researchers found that [...]

Animal testing has shaped modern drug development for decades, but its limitations become especially visible when scientists evaluate cancer immunotherapies. These treatments are designed to stimulate the immune system to recognize and destroy malignant cells, yet the same powerful immune activation can trigger life-threatening complications in patients. Researchers at the University of Rochester are developing a human-cell-based alternative: miniature tissue models known as organs-on-a-chip that could help predict these toxicities before experimental medicines reach clinical trials.

The work is being led through the university’s Translational Center for Barrier Microphysiological Systems, or TraCe-bMPS. The center is building drug-development tools around modular µSiM tissue chips, devices that contain ultrathin membranes populated with human cells. Unlike conventional laboratory cultures, these systems are engineered to reproduce key features of biological barriers, including the physical separation between tissues, controlled exposure to drugs, and measurable inflammatory responses. Their modular construction also allows the devices to be manufactured in large quantities with consistent dimensions and materials.

The platform is based primarily on acrylic components and incorporates membranes designed to mimic interfaces found in the human body. Such barriers regulate the movement of molecules and immune cells between compartments, making them central to drug absorption, toxicity, and inflammation. By assembling reproducible chips with human cells, researchers can study how a therapy affects a tissue under conditions that more closely approximate human biology than many animal models. The design also makes it possible to modify individual components for different organs or disease settings.

A major feature of the Rochester system is the integration of sensors directly into the chips. Developed in part through the work of biomedical engineering professor Benjamin Miller, these sensors can track barrier function and inflammatory signaling in real time. Instead of waiting until the end of an experiment to examine damaged cells, researchers can observe how a tissue responds as a drug is introduced. Changes in electrical or molecular signals may reveal that a barrier is becoming more permeable or that inflammatory pathways are being activated, providing an early warning of toxicity.

The immediate focus is on two severe complications associated with some cancer immunotherapies. Cytokine release syndrome, commonly called CRS, occurs when activated immune cells release large quantities of signaling proteins known as cytokines. The resulting systemic inflammation can cause fever, low blood pressure, breathing difficulties, and, in the most serious cases, organ failure. Immune effector cell-associated neurotoxicity syndrome, or ICANS, can affect the nervous system, producing confusion, seizures, impaired speech, or other neurological symptoms. Both conditions are difficult to predict reliably with animal testing because species differ in immune signaling networks and cell-surface receptors.

“The goal is to predict these toxicities from human cells on a chip, before a drug ever reaches a patient, and to do it without relying on animal models that have repeatedly failed to predict CRS in people,” says James McGrath, director of TraCe-bMPS and the William R. Kenan Jr. Professor of Biomedical Engineering. The approach does not simply attempt to reproduce a whole human body in miniature. Instead, it focuses on specific biological barriers and immune interactions that are directly relevant to the safety question being studied.

The project has now reached an important regulatory stage. The team was accepted into the US Food and Drug Administration’s Innovative Science and Technology Approaches for New Drugs, or ISTAND, pilot program. ISTAND is intended to help evaluate emerging methods that could improve drug development and eventually support regulatory decisions. Acceptance does not mean that the tissue-chip platform has already been approved for routine use, but it creates a formal pathway for the researchers to work with the FDA on defining the evidence needed for qualification.

The Rochester group is preparing a detailed qualification plan that will describe clinical considerations, timelines, data-sharing procedures, and statistical methods for evaluating the technology. If the platform ultimately receives FDA qualification, pharmaceutical companies could use its results as part of the evidence submitted in support of new drug applications. Such recognition would represent a significant step for organs-on-a-chip research, which has expanded rapidly but has only rarely progressed into formal regulatory programs.

The effort comes as US regulators seek alternatives to animal testing in preclinical safety studies. The FDA Modernization Act 2.0, enacted in 2022, opened the door for non-animal methods, while the agency’s 2025 roadmap outlined further efforts to reduce reliance on animal models. Researchers say pharmaceutical companies are showing strong interest because many immunotherapies are already in clinical development and carry risks of CRS or ICANS. The Rochester team collaborated with Graham Marsh of the Critical Path Institute and consulted with scientists at Pfizer about how the tool could fit into real-world drug development. If successful, the technology could give researchers a more human-relevant way to identify dangerous immune reactions early, helping developers eliminate unsafe candidates and refine promising treatments before patients are exposed.

Subject of Research: Human-cell tissue chips for predicting cancer immunotherapy toxicities.

Web References: University of Rochester; Translational Center for Barrier Microphysiological Systems; University of Rochester Biomedical Engineering; FDA ISTAND pilot program; FDA Modernization Act 2.0.

Image Credits: URochester photo / J. Adam Fenster.

Keywords: Drug discovery, tissue chips, organs-on-a-chip, cancer immunotherapy, cytokine release syndrome, CRS, ICANS, neurotoxicity, animal testing alternatives, biomedical engineering, microphysiological systems, human-cell models.

A protein called TRAILshort may act as a central immune brake that limits T-cell responses and CAR-T therapy. Cancer cells can weaken the immune system by producing a protein that prevents its most important defenders from attacking. Mayo Clinic researchers have identified how this protein works, revealing a possible target for treatments designed to improve [...]

Cancer researchers have reported a new strategy that combines bacterial tumor targeting, nutrient deprivation and immune stimulation in a single therapeutic design. The approach uses an engineered conjugate built from L-asparaginase and flagellin, linked to a system that directs the treatment toward calreticulin-bearing cancer cells. In experiments involving Salmonella-mediated tumor therapy, the conjugate enhanced antitumor activity compared with bacterial treatment alone, according to a study published in Cell Death Discovery.

The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.

The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.

The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.

The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.

The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.

This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.

The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.

Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.

The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.

Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.

Article Title: Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy.

Article References: Nguyen, DH., Afzal, A.R., Nguyen, P.TM. et al. Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03300-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03300-x

Keywords: cancer immunotherapy, Salmonella, calreticulin, L-asparaginase, flagellin, tumor targeting, bacterial therapy, antitumor efficacy, immunogenic cell death

A protein known for circulating in the blood to fight infection plays a very different role when produced by cells inside tumors. A protein that emerged long before animals developed circulatory systems may influence whether cancer immunotherapy succeeds. Researchers at Nagoya University in Japan found that complement C3 helps keep immunosuppressive cells out of tumors, [...]

A new analysis from a large, single-centre cohort suggests that when immune checkpoint inhibitors are given can meaningfully shape outcomes for patients with advanced cancer. The study, reported in British Journal of Cancer, examines overall survival in relation to the timing of therapy administration, moving beyond the usual question of whether immunotherapy works to asking how its scheduling may alter the odds.

Immune checkpoint inhibitors—antibodies designed to release brakes on anti-tumour T cells—have transformed treatment across multiple malignancies. Yet real-world clinical pathways are complex. Patients may begin therapy at different stages, after varying lengths of prior treatment, or under different clinical conditions that can affect both immune readiness and tumour biology.

In the cohort analysis, investigators assessed survival endpoints while stratifying by the timing of checkpoint inhibitor administration. The approach integrates observational timing variables with survival outcomes, allowing researchers to estimate whether early versus later use corresponds to measurable differences in longevity. While such designs cannot fully eliminate confounding factors—such as baseline disease severity or prior treatment intensity—the large sample and single-centre context help reduce heterogeneity.

The results indicate that overall survival is not uniform across timing categories. In practice, this means that clinical decisions about sequencing immunotherapy—relative to other systemic treatments and the patient’s progression trajectory—may influence how long patients live after starting checkpoint blockade.

Biologically, timing may affect the balance between tumour immune visibility and immune suppression. Administering therapy when tumour antigen presentation and T-cell infiltration are more favourable could support stronger initial responses. Conversely, later administration might occur after immune escape mechanisms have already hardened, potentially narrowing the window for immunological control.

Clinically, the findings encourage oncologists to treat sequencing as an active variable rather than a passive scheduling detail. Optimizing when immunotherapy enters the treatment course could improve benefit for future patients, particularly in settings where multiple lines of therapy compete.

The authors emphasize that further work, ideally incorporating prospective designs and richer biomarker data, is needed to confirm whether timing itself is the causal driver. Still, the study provides timely evidence that “when” checkpoint inhibitors are administered can matter alongside “whether.”

Overall, the viral science news takeaway is clear: immune checkpoint therapy timing may be a hidden lever in advanced cancer care, and refining it could help translate immunotherapy’s potential into more consistent survival gains.

Subject of Research: Timing of immune checkpoint inhibitor administration and overall survival in advanced cancer.

Article Title: Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.

Article References: Bosetti, T., Kennedy, O.J., Califano, R. et al. Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03494-y

DOI: https://doi.org/10.1038/s41416-026-03494-y

Image Credits: AI Generated

A newly identified inflammatory signaling target may help weaken the protective environment surrounding pancreatic tumors and make existing treatments more effective. Pancreatic tumors are not made up of cancer cells alone. They are surrounded by scar-like tissue, immune cells, and support cells that can shield the disease from treatment. A new study suggests that disrupting [...]

In a groundbreaking study poised to redefine cancer immunotherapy paradigms, researchers have unveiled a programmable RNA engineering platform that restores immune recognition in notoriously immune-resistant tumors such as prostate cancer. This innovative approach, centered on precise manipulation of mRNA alternative polyadenylation (APA), revives the expression of major histocompatibility complex class I (MHC-I) molecules — the pivotal sentinels of immune surveillance routinely downregulated in these tumors. The findings, detailed in Nature Biomedical Engineering, shed light on an elusive molecular mechanism of immune evasion and herald a new frontier in translational cancer immunology.

Prostate cancer and analogous immune-cold tumors have long bedeviled clinicians by resisting immune checkpoint inhibitor therapies, a frontline strategy in modern oncology. A primary culprit in this resistance is the diminished presentation of tumor-specific antigens on MHC-I molecules, molecules intrinsically responsible for flagging abnormal cells to cytotoxic CD8 T cells. Without adequate MHC-I display, these malignant cells evade immune detection, rendering checkpoint blockade largely ineffective. Despite the clinical significance, no therapies have yet emerged that selectively restore MHC-I expression, underscoring a critical unmet medical need.

The investigative team addressed this gap by engineering the 3′UTR CRISPR/dCas13 system (3′UTRCES), an advanced RNA-editing platform designed to modulate mRNA 3′ untranslated region (3′UTR) dynamics in vivo. Unlike conventional gene editing tools that alter DNA sequences, 3′UTRCES uniquely targets RNA transcripts’ polyadenylation sites to manipulate APA patterns — a post-transcriptional regulatory mechanism influencing mRNA stability, localization, and translation. Leveraging a catalytically inactive Cas13 (dCas13) fused to programmable effectors, this system reprograms 3′UTR architecture to reinstate normal gene expression profiles critical for immune function.

Central to their discovery is the identification of tumor-specific 3′UTR shortening in the E3 ubiquitin ligase adaptor SPSB1, a molecular player hitherto not linked to immune modulation. Through sophisticated analyses, the researchers demonstrated that aberrant SPSB1 3′UTR truncations promote enhanced ubiquitination and subsequent degradation of MHC-I molecules. This selective downregulation disrupts the immune system’s ability to recognize and eliminate malignant cells without affecting programmed death-ligand 1 (PD-L1), an immune checkpoint protein. These insights decode a novel mechanism by which tumors suppress antigen presentation, bypassing immune control.

Armed with this mechanistic understanding, the team deployed lipid nanoparticle (LNP) delivery of the 3′UTRCES constructs directly into syngeneic mouse models harboring prostate tumors. This therapeutic intervention reversed the aberrant SPSB1 3′UTR shortening, effectively restoring MHC-I expression on tumor cells. The restored antigen presentation reinvigorated the infiltration of CD8 cytotoxic T lymphocytes, amplifying antitumor immune responses and sensitizing tumors to subsequent immune checkpoint therapies. This combinatorial strategy outperformed existing modalities, offering a tangible path to overcome immune resistance.

The implications of this study extend beyond prostate cancer, representing a conceptual shift in targeting post-transcriptional gene regulation to modulate tumor immunity. By precisely tailoring RNA isoforms through 3′UTRCES, it becomes feasible to rectify pathological gene expression patterns without permanent genomic alterations, minimizing off-target effects and paving the way for tunable, reversible therapies. This technological stride potentially positions LNP-3′UTRCES as a versatile platform for broad-spectrum cancer immunotherapy.

Delving deeper into the molecular underpinnings, the research highlights how alternative polyadenylation — once considered a subtle nuance of gene regulation — plays an outsized role in immune evasion. APA events that truncate key regulatory 3′UTRs can rewire protein expression profiles, impacting ubiquitin-mediated degradation pathways. In SPSB1’s case, 3′UTR shortening shields MHC-I from stable expression, underscoring the delicate interplay between RNA processing and immune visibility. These revelations chart a new investigative avenue for uncovering APA-driven oncogenic mechanisms.

The study harnessed state-of-the-art transcriptomic and proteomic methodologies to validate the APA signatures and subsequent functional outcomes. Single-cell RNA sequencing and cross-linking immunoprecipitation unveiled the precise RNA-protein interactions modulated by 3′UTR alterations. Meanwhile, in vivo tumor growth assays meticulously quantified the therapeutic efficacy of 3′UTRCES-mediated intervention. The robust experimental design marries molecular biology with immuno-oncology, reinforcing the translational promise of RNA engineering.

Beyond prostate cancer, the researchers posit that similar APA-driven immune escape mechanisms may underpin resistance in other malignancies characterized as immune-cold or immunologically excluded. Tumor heterogeneity presents obstacles, yet the adaptability of the 3′UTRCES platform offers a pathway to customize RNA editing interventions tailored to tumor-specific APA landscapes. This precision medicine approach aligns with emerging oncology paradigms striving to unify genetic and epigenetic therapeutic targeting.

Crucially, this work confronts a longstanding conceptual bottleneck — the absence of clinically viable modalities to restore MHC-I expression selectively. Immune checkpoint inhibitors, though transformative, rely heavily on intact antigen presentation machinery to elicit durable responses. By restoring the tumor’s antigen-presenting capacity, 3′UTRCES synergizes with immune checkpoint blockade, reinvigorating exhausted cytotoxic T cells and promoting tumor clearance. This paradigm underscores the importance of targeting upstream immune suppression pathways in cancer.

The LNP delivery mechanism employed is equally noteworthy, showcasing advances in nanomedicine that enable precise nucleic acid transport to tumor sites. Lipid nanoparticles offer biocompatibility, customizable surface chemistry, and efficient endosomal escape — attributes critical for clinical translation. As the field gravitates toward RNA-based therapeutics post-COVID-19, leveraging these delivery systems in oncology sets a precedent for future innovations combining synthetic biology and immunotherapy.

Looking ahead, the scalability and safety of 3′UTRCES-mediated therapies warrant thorough exploration through preclinical and clinical studies. Immunogenicity of RNA-guided effectors, off-target RNA interactions, and durability of therapeutic responses remain important considerations. Nevertheless, the current findings provide a compelling proof of concept, invigorating translational research efforts to combat immune escape mechanisms effectively.

This pioneering research not only reframes our understanding of tumor immune evasion but also exemplifies how RNA technology can be harnessed to unlock therapeutic opportunities in recalcitrant cancers. By transforming APA from a molecular signature of immune suppression into a therapeutic target, the study opens vistas for next-generation cancer treatments that restore immune competence at the RNA level. This convergence of molecular biology, immunotherapy, and RNA engineering heralds a new dawn in oncology innovation.

In summary, the programmable editing of mRNA 3′UTRs via the 3′UTRCES platform revitalizes MHC-I expression in prostate tumors, counteracting immune suppression driven by SPSB1-mediated degradation pathways. This novel mechanistic insight, coupled with effective lipid nanoparticle delivery and demonstrated synergy with immune checkpoint inhibitors, marks a transformative advance in overcoming tumor immune resistance. The study exemplifies how precision RNA engineering can recalibrate tumor immunogenicity and redefine therapeutic potentials in cancer treatment.

As research continues to unravel the complexities of RNA-mediated regulation of immune visibility in cancer, the integration of programmable RNA tools like 3′UTRCES with established immunotherapies holds immense promise. These synergistic strategies may soon accelerate the development of personalized cancer therapies designed to circumvent immune escape and foster more durable clinical remissions. The future of oncology may indeed lie at the interface of RNA engineering and immunomodulation.

This landmark work not only elucidates a previously unrecognized molecular mechanism of immune evasion but also delivers a versatile, programmable therapeutic platform for precise post-transcriptional gene regulation in cancer. Its translational implications inspire optimism for expanding the repertoire of RNA-based interventions that can be tailored to diverse tumor contexts, ultimately enhancing patient outcomes and transforming cancer immunotherapy at its molecular roots.

---

Subject of Research: Programmable RNA engineering to restore MHC-I expression and overcome immune evasion in prostate cancer.

Article Title: Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Article References:
Huang, F., Yuan, F., Li, K. et al. Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01720-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41551-026-01720-9

Scientists may have found a completely new way to treat depression by targeting inflammation instead of brain chemistry. A small clinical trial led by researchers at the University of Bristol suggests that targeting the immune system could help people with depression who do not improve with standard antidepressant medications. The findings, published May 20 in [...]